BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Positive Long-Term Clinical Data on Ventus Medical's Provent(R) Sleep Apnea Therapy Published


10/17/2011 11:36:42 AM

BELMONT, Calif., Oct. 17, 2011 /PRNewswire/ -- Ventus Medical today announced that the results of a large, long-term study of its proprietary Provent® Sleep Apnea Therapy, an innovative, non-invasive treatment for obstructive sleep apnea (OSA), were published in the November 2011 issue of the Journal of Clinical Sleep Medicine, an official publication of the American Academy of Sleep Medicine.

(Photo: http://photos.prnewswire.com/prnh/20110209/SF45785-b)

(Photo: http://photos.prnewswire.com/prnh/20110209/SF45785-a)

"This study provides further validation that Provent Therapy is an effective treatment for some OSA patients as it reduces daytime sleepiness, apnea hypopnea index (AHI) and snoring associated with this prevalent condition," said Meir Kryger, M.D., of Gaylord Sleep Medicine and past president of the American Academy of Sleep Medicine. "Patients reported wearing the device almost 90 percent of the nights, which represents very high compliance. The current gold standard, continuous positive airway pressure (CPAP) is very effective but many patients do not use it adequately. Provent represents an important new treatment option for many obstructive sleep apnea patients."

About the Study

The 13-center, 12-month study was an extension of the 3 month study that was previously published in the Journal SLEEP. Patients who were compliant with the device and demonstrated adequate treatment were enrolled for this extension study. These patients showed a 70 percent reduction in the median AHI after 12 months of treatment with Provent Therapy. AHI is a measure of number of breathing pauses per hour of sleep. In addition, the study confirmed a very high nightly compliance rate of 89 percent. Epworth Sleepiness Scale (a measure of sleepiness) was reduced five points and snoring was reduced by 74 percent. The publication of the data can be found at: http://www.aasmnet.org/jcsm/currentissue.aspx.

"As we expand our footprint in the United States and international markets, we believe it is critically important to have solid peer-reviewed, high quality research like this study to validate the benefits of using Provent Therapy to treat OSA," said Peter Wyles, President and Chief Executive Officer of Ventus Medical. "We commend Dr. Kryger and his colleagues on the results of this important long-term study."

About Provent® Sleep Apnea Therapy

Provent is a proprietary medical device used for the treatment of obstructive sleep apnea (OSA). The device has been shown to be clinically effective in a series of peer-reviewed studies. It is an easy to use, non-invasive and disposable treatment that works across mild, moderate, and severe OSA. Provent Therapy utilizes nasal expiratory positive airway pressure (EPAP) to keep a patient's airway open during sleep and has been clinically proven in numerous studies to reduce sleep apnea. It incorporates a novel MicroValve design that is placed over the nostrils and secured with hypoallergenic adhesive. During inhalation, the valve opens allowing nearly unobstructed airflow. During exhalation, the valve closes, limiting airflow through small openings, which increases expiratory pressure and keeps the airway open, preventing disruption in breathing. Provent® Therapy is accepted onto the Australian Register of Therapeutic Goods (ARTG), is FDA cleared and has CE marking. For more information, please visit www.proventtherapy.com.

About Ventus Medical

Ventus Medical is a privately-held medical device company dedicated to providing non-invasive medical solutions for people with sleep-disordered breathing. Based on its innovative MicroValve technology and patented designs, Ventus has developed a unique line of clinically-proven medical devices to address the continuum of sleep disorders from severe obstructive sleep apnea (OSA) to mild snoring. Ventus Medical devices work by creating expiratory positive airway pressure (EPAP). The company markets Provent® Therapy, a discreet, easy-to-use nasal device, for the treatment of obstructive sleep apnea in the United States, Australia, Hong Kong and India, and is developing an over-the-counter device for snoring. www.ventusmedical.com.

SOURCE Ventus Medical



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES